A phase I randomized placebo controlled trial of the safety of 3% SPL7013 Gel (VivaGel®) in healthy young women administered twice daily for 14 days - PubMed (original) (raw)

Clinical Trial

A phase I randomized placebo controlled trial of the safety of 3% SPL7013 Gel (VivaGel®) in healthy young women administered twice daily for 14 days

Craig R Cohen et al. PLoS One. 2011.

Abstract

Objective: To assess the safety of VivaGel® used vaginally twice daily for 14 days among healthy, sexually-abstinent women, aged 18-24 years in the USA and Kenya.

Design: Randomized placebo controlled trial.

Methods: Participants were randomized 2∶1, VivaGel to placebo. Safety was assessed by comparing genitourinary (GU) adverse events (AEs), colposcopy findings, vaginal lactobacilli and laboratory abnormalities by arm.

Results: Fifty-four women were enrolled; 35 in the VivaGel arm and 19 in the placebo arm. Twenty-six (74%) and 10 (53%) women reported taking all doses of VivaGel and placebo, respectively. No grade 3 or 4 AEs, or serious AEs occurred. Twenty-five (71%) participants in the VivaGel arm compared to 10 (53%) participants in the placebo arm had at least one grade 1 or 2 GU AE associated with product use (RR = 1.4, 95% CI 0.8-2.2). All seven grade 2 GU AEs associated with product use occurred among four women in the VivaGel arm. Vulvar and cervical erythema, cervical lesions, symptomatic BV, urinary frequency and metrorrhagia were more common in the VivaGel arm than the placebo arm. Twenty-nine (83%) participants in the VivaGel arm had a colposcopic finding compared to 10 (53%) participants in the placebo arm (RR = 1.6, 95%CI = 1.0-2.5). Two women in the VivaGel arm prematurely discontinued product use themselves due to a reported GU AE. Persistence of H₂O₂-producing and non-producing lactobacilli did not differ by study arm.

Conclusions: GU AEs and colposcopic findings consistent with mild epithelial irritation and inflammation occurred more commonly among women in the VivaGel arm.

Trial registration: ClinicalTrials.gov NCT003311032.

Trial registration: ClinicalTrials.gov NCT00331032.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: Both Jeremy Paull and Clare Price are employees of StarPharma Ltd, the company developing VivaGel. Jeremy Paull and Clare Price served on the protocol team and supported implementation of the trial. In regards to the manuscript, they made suggested changes to the Introduction, Methods and Results, but not to the interpretation of the results due to potential conflict of interest. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.

Figures

Figure 1. Flow of participants.

References

1. UNAIDS . Report on the global AIDS epidemic; 2008. Joint United Nations Programme on HIV/AIDS.
1. National AIDS and STI Control Programme MoH K. Kenya AIDS Indicator Survey 2007: Preliminary Report. 2008.
1. Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect. 1999;75:3–17. -PMC -PubMed
1. Gong E, Matthews B, McCarthy T, Chu J, Holan G, et al. Evaluation of dendrimer SPL7013, a lead microbicide candidate against herpes simplex viruses. Antiviral Res. 2005;68:139–146. -PubMed
1. Bourne N, Zaneveld LJ, Ward JA, Ireland JP, Stanberry LR. Poly(sodium 4-styrene sulfonate): evaluation of a topical microbicide gel against herpes simplex virus type 2 and Chlamydia trachomatis infections in mice. Clin Microbiol Infect. 2003;9:816–822. -PubMed

A phase I randomized placebo controlled trial of the safety of 3% SPL7013 Gel (VivaGel®) in healthy young women administered twice daily for 14 days - PubMed (original) (raw)